AstraZeneca and Astellas strike Japan Symbicort alliance
05 August 2009
Ian Haydock
Please Login to read the full article.
05 August 2009
Ian Haydock
ian.haydock@informa.com
Astellas is to co-promote AstraZeneca's inhaled combination drug Symbicort (budesonide plus formoterol) for bronchial asthma in Japan, in a deal worth ¥3.0 billion ($31.5 million) up front to the UK firm.
AstraZeneca will manufacture the product, with Astellas to distribute and market...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Does Vectura's US deal on respiratory drug mean FDA is softening on approval pathway?
- Pivotal trials boost Relovair from GSK/ Theravance in COPD
- GSK to close three research units, open four more amid hopes for sales growth in 2012
- GSK sees £3 billion wiped off value in response to mixed Phase III Relovair data
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
